Company Announces Participation in BTIG Virtual Biotechnology Conference
LEXINGTON, Mass.–(BUSINESS WIRE)–Immuno-oncology leader, Agenus (Nasdaq: AGEN), today announced the Company will release its second quarter 2023 financial results via press release before the market opens on Tuesday, August 8, 2023.
In addition, Dr. Garo Armen, Chairman and CEO of Agenus, will participate in the following upcoming investor conferences:
- BTIG Virtual Biotechnology Conference 2023 – Fireside chat presentation will be held virtually on Monday, August 7th, 2023 at 3:00 PM ET.
A replay of the fireside chat from the BTIG conference can be accessed on the company’s website at https://investor.agenusbio.com/events-and-presentations following the event.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The Company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics), and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us on LinkedIn and Twitter @agenus_bio.
Contacts
Investor Contact
Zack Armen
917-362-1370
investors@agenusbio.com
Media Contact
781-674-4784
communications@agenusbio.com